Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems (Dual Stage Ultrafilter or DSU). The company is a smaller reporting company with operations in the U.S. and Europe.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Product Revenues | $631 | $387 |
| Gross Margin | $179 (28.4%) | $149 (38.5%) |
| Net Loss | $(735) | $(1,640) |
| Net Loss Per Share | $(0.02) | $(0.04) |
| Cash and Cash Equivalents | $1,651 | $2,505 |
| Total Assets | $3,172 | $4,036 |
| Total Liabilities | $1,411 | $1,502 |
| Stockholders' Equity | $1,761 | $2,534 |
Liquidity: Cash decreased by $655,000 during the quarter. Net cash used in operating activities was $660,000.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 63% to $631,000, driven primarily by a $311,000 increase in revenue from a contract with the Office of U.S. Naval Research and $24,000 in new DSU sales. This offset a $91,000 decline in European MD filter sales due to production delays and currency fluctuations.
- Cost of Goods Sold (COGS): COGS rose 90% to $452,000, largely due to costs associated with the Naval Research contract and DSU sales.
- Operating Expenses: Total operating expenses decreased 52% to $919,000.
- R&D: Dropped 92% to $58,000 as clinical trials for the H2H product were completed in 2008.
- SG&A: Decreased 29% to $789,000 due to staff reductions, lower legal fees, and reduced recruiting costs, partially offset by increased marketing for the DSU.
- Net Loss Improvement: Net loss narrowed significantly to $735,000 from $1,640,000, aided by the absence of a $114,000 impairment loss on auction rate securities recorded in Q1 2008.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern. Management projects a need to raise additional funds through licensing, asset sales, or equity offerings before the end of 2009.
- Delisting Risk: The company received notice from the NYSE Alternext US LLC (formerly AMEX) of an application to strike its common stock due to noncompliance with listing standards regarding stockholders' equity and sustained net losses. Trading was suspended on January 22, 2009, and the stock now trades on the OTC Bulletin Board.
- Regulatory Status: The FDA requested additional information regarding the DSU application for dialysis clinics; a response was provided in February 2009 with a 90-day review period. The company is also pursuing a $2 million Department of Defense appropriation for water filtration development.
- Legal Proceedings: Two pending employee claims exist: one in France for approximately $42,000 (company disputes liability) and one in the U.S. for breach of contract/fraud (loss limited to $10,000 deductible).
Investor Verification Checklist
- Cash Runway: Verify the timeline for raising capital given the $1.65 million cash balance and $660,000 quarterly burn rate.
- Delisting Status: Confirm the final status of the AMEX delisting application and the impact on liquidity and investor base.
- Government Contracts: Assess the certainty of the $2 million Department of Defense appropriation and the status of the FDA review for the DSU product.
- European Sales: Investigate the resolution of production delays affecting European MD filter shipments.
- Customer Concentration: Note that two customers accounted for 95% of sales in Q1 2009 (42% and 53%), creating significant concentration risk.